Citizens JMP analyst Jason Butler lowered the firm’s price target on Prothena (PRTA) to $11 from $29 and keeps an Outperform rating on the shares. Prothena last week reported results from cohort A of the Phase 1 PRX012 in Alzheimer’s disease patients, with results demonstrating a favorable reduction in amyloid levels at the 200mg and 400mg doses, but this benefit was accompanied by elevated, uncompetitive ARIA incidence in PRX012-treated patients, the analyst tells investors in a research note. The ARIA AE profile likely makes PRX012 competitively unviable in early-stage AD patients, the firm says.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRTA:
- Prothena price target lowered to $15 from $81 at Piper Sandler
- Prothena Announces Promising Phase 1 Results for PRX012
- Prothena announces Novo Nordisk to advance coramitug into Phase 3
- Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk
- Prothena’s Strategic Initiatives and Promising Alzheimer’s Pipeline Drive Buy Rating